BRAF and melanoma: A longer median PFS (16.2 vs. 12.0 months, respectively; p = 0.042) with a higher rate of grade 3 adverse events (55% vs. 33%) were also reported in dabrafenib, and trametinib plus spartalizumab than dabrafenib and trametinib for BRAF(V600)-mutant advance melanoma [123].